Valuation: AtaiBeckley

Market Cap 272.59Cr 243.31Cr 224.47Cr 203.93Cr 382.58Cr 26TCr 388.46Cr 2.7TCr 1.07TCr 14TCr 1.02TCr 1TCr 43TCr P/E 2024
-1.43x
P/E 2025 -1.4x
Enterprise Value 247.44Cr 220.86Cr 203.76Cr 185.12Cr 347.29Cr 23TCr 352.62Cr 2.45TCr 966.94Cr 12TCr 928.79Cr 908.89Cr 39TCr EV / Sales 2024
60,95,88,266x
EV / Sales 2025 30,18,04,774x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day+0.82%
3 months+3.01%
6 months+50.92%
Current year+79.71%
Current year 3.26
Extreme 3.265
7.45
1 year 3.26
Extreme 3.265
7.45
3 years 1.02
Extreme 1.025
7.45
5 years 1.02
Extreme 1.025
17.81
10 years 1.02
Extreme 1.025
22.91
Date Insider Type Main position Quantity % Market Cap. Importance
11/09/26 Issuer sale

Chief Executive Officer

-1,01,79,823 2.7449%
11/09/26 Issuer sale

Director

-7,41,089 0.1998%
11/09/26 Issuer sale

Director

-4,30,968 0.1162%

Financials

2024 2025
Net sales 0.31 0.27 0.25 0.23 0.43 29.17 0.44 3.06 1.2 15.29 1.16 1.13 48.42 4.09 3.65 3.37 3.06 5.74 387.33 5.83 40.56 15.98 202.93 15.35 15.02 642.86
Net income -15Cr -13Cr -12Cr -11Cr -21Cr -1.41TCr -21Cr -148.08Cr -58Cr -740.78Cr -56Cr -55Cr -2.35TCr -66Cr -59Cr -54Cr -49Cr -93Cr -6.25TCr -94Cr -654.79Cr -257.93Cr -3.28TCr -247.76Cr -242.45Cr -10TCr
Net Debt -3.54Cr -3.16Cr -2.92Cr -2.65Cr -4.97Cr -335.55Cr -5.05Cr -35Cr -14Cr -175.8Cr -13Cr -13Cr -556.92Cr -25Cr -22Cr -21Cr -19Cr -35Cr -2.38TCr -36Cr -249.46Cr -98Cr -1.25TCr -94Cr -92Cr -3.95TCr
Projected Income Statement - Annual - AtaiBeckley
Logo AtaiBeckley
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
Employees
99
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - AtaiBeckley
  1. Stock Market
  2. Stocks
  3. ATAI Stock